SUPN Q3 2021 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$148M-4.3% YoY

Gross Profit

$130M87.8% margin

Operating Income

$33M22.0% margin

Net Income

$22M14.5% margin

EPS (Diluted)

$0.40

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$745M

Stockholders' Equity

$810M

Cash & Equivalents

$215M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$148M	$155M	-4.3%
Gross Profit	$130M	$134M	-2.5%
Operating Income	$33M	$56M	-41.9%
Net Income	$22M	$40M	-46.1%

Revenue Segments

Product

$146M50%

Trokendi Xr

$81M28%

Oxtellar X R

$30M10%

APOKYN

$25M8%

MYOBLOC

$5M2%

XADAGO

$3M1%

Royalty

$3M1%

Qelbree

$2M1%